Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Experimental Pharmacology and Drug Discovery
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1503490
This article is part of the Research Topic Exploring Untapped Potential: Innovations in Drug Repurposing View all 4 articles

Salidroside enhances 5-Fluorouracil sensitivity against hepatocellular carcinoma via YIPF5-induced mitophagy

Provisionally accepted
Sumin Sun Sumin Sun 1Sheng Huan Sheng Huan 2Haili Hu Haili Hu 1Long Chen Long Chen 1Jiahui Chen Jiahui Chen 1Peihua Sun Peihua Sun 1Xiaoqing Dong Xiaoqing Dong 3*
  • 1 Nanjing Normal University, Nanjing, Jiangsu Province, China
  • 2 First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China
  • 3 Nanjing Drum Tower Hospital, Nanjing, China

The final, formatted version of the article will be published soon.

    Hepatocellular carcinoma (HCC) is a major medical challenge due to its high incidence and poor prognosis. 5-Fluorouracil (5-FU), although extensively studied in the treatment of HCC and other solid tumors, has limited application as a first-line therapy for HCC due to its resistance and significant inter-patient variability. To address these issues, researchers have explored drug repurposing. One of our key findings in this endeavour was the potent anti-HCC effect of the natural product Salidroside (Sal) when co-administered with 5-FU. Sal was found to inhibit mitosis and promote cellular senescence in HCC cells via a mechanism distinct from 5-FU, specifically by inducing excessive mitophagy that led to cellular mitochondrial dysfunction. Importantly, YIPF5 was confirmed as a potential molecular target of Sal. This natural product modulated YIPF5-induced mitophagy and influenced both mitosis and senescence in HCC cells. The combination of Sal and 5-FU demonstrated significant therapeutic effects in a mouse HCC model. In conclusion, our study was not only in line with the innovative strategy of drug repurposing, but also important for drug design and natural product screening targeting the relevant pathways.

    Keywords: Salidroside, 5-fluorouracil, mitophagy, senescence, Mitosis, Hepatocellular Carcinoma

    Received: 29 Sep 2024; Accepted: 06 Dec 2024.

    Copyright: © 2024 Sun, Huan, Hu, Chen, Chen, Sun and Dong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Xiaoqing Dong, Nanjing Drum Tower Hospital, Nanjing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.